Clinics in Dermatology
Volume 28, Issue 1 , Pages 17-23 , January 2010

Hormonal therapy for acne: why not as first line therapy? facts and controversies

References 

  1. Gollnick H, Cunliffe W, Berson D, et al. Management of acne. J Am Acad Dermatol 2003;49:s2-s5, s20-25.
  2. Pochi PE, Strauss JS. Endocrinologic control of the development and activity of the human sebaceous gland. J Invest Dermatol. 1974;62:191–201
  3. Ebling FJ. Hormonal control and methods of measuring sebaceous gland activity. J Invest Dermatol. 1974;62:161–171
  4. Thiboutot DM, Knaggs H, Galiland K, et al. Activity of type 1 5 alpha reductase is greater in the follicular infrainfundibulum compared with the epidermis. Br J Dermatol. 1997;136:166–171
  5. Cunliffe WJ, Simpson NB. Disorders of the sebaceous gland. In:  Champion RH,  Burton JL,  Burns DA, et al. editor. Textbook of dermatology. 6th ed.. Oxford: Blackwell Science; 1998;p. 1927–1984
  6. Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56:651–663
  7. Drucker WD, Blumberg JM, Gandy HM, et al. Biologic activity of dehydroepiandrosterone sulfate in man. J Clin Endocrinol Metab. 1972;35:48–54
  8. Darley CR, Moore JW, Besser GM, et al. Androgen status in women with late onset or persistent acne vulgaris. Clin Exp Dermatol. 1984;9:28–35
  9. Lucky AW, McGuire J, Rosenfield RL, et al. Plasma androgens in women with acne vulgaris. J Invest Dermatol. 1983;81:70–74
  10. Mathur RS, Moody LO, Landgrebe S, et al. Plasma androgens and sex hormone binding globulin in the evaluation of hirsute females. Fertil Steril. 1981;35:296–305
  11. Schiavone FE, Rietschel RL, Sgoutas D, et al. Elevated free testosterone levels in women with acne. Arch Dermatol. 1983;119:799–802
  12. Scholl GM, Wu CH, Leyden J. Androgen excess in women with acne. Obstet Gynecol. 1984;64:683–688
  13. Strauss JS, Klingman AM, Pochi PE. The effects of androgens and estrogens on human sebaceous glands. J Invest Dermatol. 1962;39:139
  14. Carmina E, Lobo RA. Evidence for increased androsterone metabolism in some normoandrogenic women with acne. J Clin Endocrinol Metab. 1993;76:1111–1114
  15. Odlind V, Carlstrom K, Michaelsson C, et al. Plasma androgenic activity in women with acne vulgaris and in healthy girls before, during and after puberty. Clin Endrocrinol. 1982;16:243–249
  16. Vexiau P, Husson C, Chivot M, et al. Androgen excess in women with acne alone compared with women with acne and/or hirsutism. J Invest Dermatol. 1990;94:279–283
  17. Katsambas A, Papakonstantinou A. Acne: systemic treatment. Clin Dermatol. 2004;22:412–418
  18. Lucky A. Hormonal correlates of acne and hirsutism. Am J Med. 1995;98:89S–94S
  19. Greenwood R, Brummitt L, Burke B, et al. Treatment of acne with either tetracycline, oestrogen/cyproterone acetate or combined therapy: a double-blind laboratory and clinical study. Br Med J. 1985;291:1231–1235
  20. Miller JA, Wojnarowska FT, Dowd PM, et al. Anti-androgen treatment in women with acne: a controlled trial. Br J Dermatol. 1986;114:705–716
  21. Chen W, Thiboutot D, Zouboulis CC. Cutaneous androgen metabolism: basic research and clinical perspectives. J Invest Dermatol. 2002;119:992–1007
  22. Thiboutot D, Jabara S, McAllister JM, et al. Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol. 2003;120:905–914
  23. Katsambas A, Dessinioti C. New and emerging treatments in dermatology: acne. Dermatol Ther. 2008;21:86–95
  24. Faure M, Drapier-Faure E. L' acné. Les traitements hormonaux. Ann Dermatol Venereol. 2003;130:142–147
  25. Stewart ME, Greenwood R, Cunliffe WJ, et al. Effect of cyproterone acetate-ethinyl estradiol treatment on the proportion of linoleic and sebaceic acids in various skin surface lipid classes. Arch Dermatol Res. 1996;278:481–485
  26. Thiboutot D. Endocrinologic evaluation and hormonal therapy for women with difficult acne. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):57–61
  27. Van Wayjen R, van den Ende A. Experience in the long-term treatment of patients with hirsutism and/or acne with cyproterone acetate-containing preparations: efficacy, metabolic, and endocrine effects. Exp Clin Endocrinol Diabetes. 1995;103:241–251
  28. Gollnick H, Albring M, Brill K. Efficacité de l'acètate de cyprotèrone oral associé à l'ethinylestradiol dans le traitement de l'acné tardive de type facial. Ann Endocrinol. 1999;60:157–166
  29. Mallari R, Sinclair RD. Shortness of breath: an uncommon side-effect of cyproterone acetate in the treatment of androgenetic alopecia. Int J Dermatol. 2002;41:946–947
  30. Thiboutot D. Acne: hormonal concepts and therapy. Clin Dermatol. 2004;22:419–428
  31. Akamatsu H, Zouboulis CC, Orfanos CE. Spironolactone directly inhibits proliferation of cultured human facial sebocytes and acts antagonistically to testosterone and 5-alpha-dihydrotestosterone in vitro. J Invest Dermatol. 1993;100:660–662
  32. Lowenstein EJ. Diagnosis and management of the dermatologic manifestations of the polycystic ovary syndrome. Dermatol Ther. 2006;19:210–223
  33. Krunic A, Giurea A, Scheman A. Efficacy and tolerance of acne treatment using both spironolactone and a combined contraceptive containing dorspirenone. J Am Acad Dermatol. 2008;58:60–62
  34. Leyden J, Shalita A, Hordinsky M, et al. Efficacy of a low-dose oral contraceptive containing 20 μg of ethinyl estradiol and 100 μg of levonorgestrel for the treatment of moderate acne: a randomized, placebo-controlled trial. J Am Acad Dermatol. 2002;47:399–409
  35. Thorneycroft I. Evolution of progestins. Focus on the novel progestin drospirenone. J Reprod Med. 2002;47(suppl 11):975–980
  36. Thiboutot D. Regulation of human sebaceous glands. J Invest Dermatol. 2004;123:1–12
  37. Lucky AW, Henderson TA, Olson WH, et al. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris. J Am Acad Dermatol. 1997;37:746–754
  38. Redmond GP, Olson WH, et al. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial. Obstet Gynecol. 1997;89:615–622
  39. Thiboutot D, Archer DF, Lemay A, et al. A randomized, controlled trial of a low-dose contraceptive 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment. Fertil Steril. 2001;76:461–468
  40. Koltun W, Lucky AU, Thiboutot D, et al. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial. Contraception. 2008;77:249–256
  41. James WD. Acne. N Engl J Med. 2005;352:1463–1472
  42. Arowojolu AO, Gallo MF, Grimes DA, et al. Combined oral contraceptive pills for treatment of acne. Cochrane Database Syst Rev. 2004;CD004425
  43. Thorneycroft IH, Gollnick H, Schellschmidt I. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment. Cutis. 2004;74:123–130
  44. Harper JC. Antiandrogen therapy for skin disease and hair disease. Dermatol Clin. 2006;24:137–143
  45. DeRossi SS, Hersh EV. Antibiotics and oral contraceptives. Dent Clin North Am. 2002;46:653–654
  46. Helms SE, Bredle DL, Zajic J, et al. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 1997;36:705–710
  47. London BM, Lookingbill DP. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives. Arch Dermatol. 1994;130:392–393
  48. Degitz K, Placzek M, Arnold B, et al. Congenital adrenal hyperplasia and acne in male patients. Br J Dermatol. 2003;148:1263–1266
  49. Zouboulis C, Picero-Martin J. Update and future of systemic acne treatment. Dermatology. 2003;206:37–53
  50. Orfanos CE, Adler YD, Zouboulis CC. The SAHA sydnrome. Horm Res. 2000;54:251–258
  51. Bunker CB, Newton JA, Kilborn J, et al. Most women with acne have polycystic ovaries. Br J Dermatol. 1989;121:675–680
  52. Hart R, Hickey M, Franks S. Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2004;18:671–683
  53. World Health Organization . Improving access to quality care in family planning: medical eligibility criteria for contraceptive use. 2nd ed. WHO: Geneva; 2003;
  54. Frangos J, Alavian CN, Kimball AB. Acne and oral contraceptives: update on women's health screening guidelines. J Am Acad Dermatol. 2008;58:781–786
  55. Hamani Y, Sciaki-Tamir Y, Deri-Hasid R, et al. Misconceptions about oral contraception pills among adolescents and physicians. Human Reprod. 2007;22:3078–3083
  56. Tan JK. Psychosocial impact of acne vulgaris: evaluating the evidence. Skin Ther. 2004;9:1–3
  57. Speroff L., Fritz M.A. Clinical gynecologic endocrinology and infertility, 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 897, 900-2, 912, 916.
  58. Kemmeren JM, Tanis BC, vandenBosch MAAJ, et al. Risk of arterial thrombosis in relation to oral contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke. 2002;33:1202–1208
  59. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception . Ischaemic stroke and combined oral contraceptives: results of an international, multicenter, case-control study. Lancet. 1996;348:498–505
  60. CSM . Cyproterone acetate (Dianette): risk of venous thromboembolism (VTE). Curr Prob Pharmacovigil. 2002;28:9–10
  61. WHO . Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1582–1588
  62. Pini M, Scoditti U, Caliumi F, et al. Risk of venous thromboembolism and stroke associated with oral contraceptives. Role of congenital thrombophilias. Recenti Prog Med. 1996;87:331–337
  63. Parkin L, Skegg DC, Wilson M, et al. Oral contraceptives and fatal pulmonary embolism. Lancet. 2000;355:2133–2134
  64. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet. 2001;358:1427–1429
  65. Farmer RD, Lawrenson RA, Todd JC, et al. Oral contraceptives and venous thromboembolic disease. Analyses of the UK General practice research database and the UK Mediplus database. Hum Reprod Update. 1999;5:688–706
  66. Franks S, Layton A, Glasier A. Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Human Reprod. 2008;23:231–232
  67. Vessey M, Painter R. Oral contraceptives use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006;95:385–389
  68. Moreno V, Bosch F, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: The IARC Multicentric Case-control Study. Lancet. 2002;359:1085–1092
  69. Smith J, Green J, de Gonzalez A, et al. Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet. 2003;361:1159–1167
  70. Royar J, Becher H, Chang-Claude J. Low-dose oral contraceptives: protective effect on ovarian cancer risk. Int J Cancer. 2001;95:370–374
  71. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. SHARE study group. Steroid Hormones and Reproductions. Am J Epidemiol. 2000;152:233–241
  72. American College of Obstetricians and Gynecologists . Oral contraceptives for adolescents: benefits and safety. Washington (DC): ACOG; 1999;
  73. Expert Working Group Meeting to update the selected practice recommendations for contraceptive use. Selected practice recommendations for contraceptive use. 2nd ed.. World Health Organization: Geneva; 2004;
  74. World Health Organization and US Agency for international development . Recommendations for updating selected practices in contraceptive use. Vol 1. Washington, DC: World Health Organization and US Agency for International Development; 1994;

PII: S0738-081X(09)00052-2

doi: 10.1016/j.clindermatol.2009.03.006

Clinics in Dermatology
Volume 28, Issue 1 , Pages 17-23 , January 2010

Article Tools